Fluicell AB (publ) (STO:FLUI)

Market Cap	41.62M +106.1%
Revenue (ttm)	18.44M +837.9%
Net Income	2.80M
EPS	2.03
Shares Out	1.37M
PE Ratio	14.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,186
Open	30.30
Previous Close	30.30
Day's Range	29.00 - 30.30
52-Week Range	7.65 - 67.20
Beta	2.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Fluicell AB

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Bio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUI

Financial Performance

In 2025, Fluicell AB's revenue was 6.00 million, an increase of 222.86% compared to the previous year's 1.86 million. Losses were -8.33 million, -46.28% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error